Teleflex Inc Stock Price, News & Analysis

DW Healthcare Partners has successfully closed the sale of Z-Medica to Teleflex (NYSE: TFX). Z-Medica specializes in manufacturing hemostatic products crucial for controlling bleeding. DWHP initially invested in Z-Medica in 2012, significantly growing the business through product development and channel diversification. This sale follows Z-Medica's successful evolution into a major player in the hemostatic market, largely attributed to strategic partnerships and innovative products like QuickClot Control+®.

Teleflex (NYSE:TFX) has successfully completed the acquisition of Z-Medica for $500 million, with a potential additional $25 million based on performance milestones. This strategic buy aims to enhance Teleflex's medical technology portfolio, specifically in hemorrhage control products, which are critical for healthcare providers. The acquisition is not anticipated to have a significant impact on 2020 revenue but is expected to contribute between $60 million and $70 million in revenue and $0.07 to $0.15 in adjusted EPS for 2021, with potential for high-single digit growth thereafter.

Teleflex Incorporated has been recognized as one of the best places to work in medical sales for the fourth consecutive year, according to MedReps.com’s 2021 survey. Teleflex ranked first in the Large Category for Best Medical Device Companies and second overall among medical sales companies. The survey, which included over 2,000 respondents, highlights the company's positive corporate culture and commitment to employee welfare during the COVID-19 pandemic. Teleflex emphasizes innovation and values that prioritize both patient care and employee experience.

Teleflex announced positive results from four studies on the UroLift System for treating benign prostatic hyperplasia (BPH) at the ICS 2020 Annual Meeting. These studies confirm the safety and efficacy of the UroLift System, demonstrating significant symptom improvement for men suffering from BPH. With over 40% of men over 50 affected by BPH, the treatment is becoming a preferred option. Key findings included high catheter independence rates (86%-87%) and notable symptom relief, reinforcing the UroLift System as a minimally invasive solution that maintains sexual function.

Teleflex Incorporated (NYSE: TFX) announced that Liam Kelly, Chairman, President, and CEO, will speak at the Stephens Investment Conference on November 16, 2020, at 1:00 p.m. ET. A live audio webcast of the presentation, along with the slide presentation, will be accessible on the investor section of Teleflex's website. Teleflex is dedicated to enhancing healthcare through innovative medical technologies across various fields, including vascular access, anesthesia, and respiratory care.

Teleflex Incorporated (NYSE: TFX) announced a quarterly cash dividend of $0.34 per share of common stock. This dividend will be paid on December 15, 2020 to shareholders recorded as of November 15, 2020. Teleflex is committed to providing medical technologies that enhance the health and quality of life of patients. The company focuses on innovation to meet clinical needs across diverse fields including vascular access, urology, and emergency medicine. For more details, visit teleflex.com.

Teleflex reported third quarter 2020 revenues of $628.3 million, a decline of 3.1% year-over-year. GAAP diluted EPS was $2.46, down 49.3% from $4.85 in the previous year. Adjusted EPS fell 6.7% to $2.77. Revenue was adversely affected by the COVID-19 pandemic, with an estimated $78 million impact, contributing to a 12% revenue loss. Despite these challenges, growth was noted in the Interventional Urology sector and Vascular Access products. The company announced an acquisition of Z-Medica, LLC, expected to enhance earnings per share in 2021.

Teleflex Incorporated (NYSE: TFX) has entered a definitive agreement to acquire Z-Medica, LLC for $500 million plus potential performance bonuses of $25 million. The acquisition, aimed at enhancing Teleflex's portfolio in hemostatic products, is expected to close in Q4 2020, pending regulatory approvals. Z-Medica's innovative products, including QuikClot and Combat Gauze, are poised to boost Teleflex's revenue by $60-$70 million in fiscal 2021 and enhance earnings per share. The deal aligns with Teleflex's strategy to invest in high-growth medical technologies.

Teleflex (NYSE: TFX) expands its UroLift portfolio with the new UroLift Advanced Tissue Control (ATC) System, aimed at enhancing treatment for benign prostatic hyperplasia (BPH). Cleared by the FDA in June 2020, the UroLift ATC System offers advancements in treating complex prostate anatomies, allowing urologists to more effectively manage obstructive median lobes and large lateral lobes. Early feedback from urologists indicates satisfaction with its usability and effectiveness. The UroLift System has shown significant positive outcomes in patient symptoms and quality of life, establishing its credibility in the market.